Abstract

▼Relvar Ellipta 92μg/22μg (GSK) is a dry powder inhaler that contains a corticosteroid (fluticasone furoate) and a long-acting beta₂ agonist (vilanterol trifenatate).1 Neither ingredient is currently marketed as a single-ingredient inhalation product, although fluticasone furoate is available as a nasal spray for the treatment of allergic rhinitis. Relvar Ellipta 92μg/22μg is licensed for once-daily use as maintenance therapy for chronic obstructive pulmonary disease (COPD) and asthma. In this article we consider the evidence for its use in the management of patients with COPD. An article in a future issue will review its use in the management of patients with asthma.